Goodyear Tire & Rubber Co vs Johnson & Johnson — how do they compare? Goodyear Tire & Rubber Co trades at $4.68 (market cap $1.37B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 451.2× Goodyear Tire & Rubber Co's market cap, and Johnson & Johnson pays a 2.09% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and Johnson & Johnson for 129 Days on average.
| GT | JNJ | |
|---|---|---|
Market Cap | $1.37B | $618.09B |
Volume | 9,470,773 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $278.43 |
52-Week Low | $4.66 | $186.00 |
Typical Hold Time | 57 Days | 129 Days |
Enterprise Value | $8.72B | $646.37B |
Dividend Yield | — | 2.09% |
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $4.68, down 0.21% on the day, reflecting persistent bearish technicals and weak profitability. The stock shows deeply discounted valuation ratios with a P/E of 4.69 and P/B of 0.48, but fundamentals are challenged by a net loss of $1.72 billion in 2025 and negative margins. Recent news highlights the company's ongoing turnaround efforts, including restructuring and a focus on premium tire segments, amid significant cash flow volatility and high debt levels.
The outlook remains cautious with a consensus analyst price target of $8.00 suggesting potential upside, but execution risks on margin improvement and debt management are critical. Investment opportunity hinges on successful restructuring, while risks include competitive pressures, volume declines, and macroeconomic headwinds impacting the auto sector.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →